CogState Aktie

CogState ROE

Delisted·15. jun. 2026

ROE (Return on Equity) for CogState (CGS.AX) pr. 23. aug. 2026 er 21,18 %. I foregående år var ROE (Return on Equity) 13,32 % — en ændring på 59,03 % (højere).

ROE

21,18 %

YoY

59,03%

Senest opdateret:

I 2026 var egenkapitalrentabiliteten (ROE) for CogState 21,18 %, en stigning på 59,03% sammenlignet med 13,32 % ROE i det foregående år.

CogState ROE historik

  • 3 år

  • 10 år

  • 25 år

  • Maks

ROE
Date
ROE
1. jan. 2018
-4,84 USD
1. jan. 2019
-24,68 USD
1. jan. 2020
-12,63 USD
1. jan. 2021
24,02 USD
1. jan. 2022
22,84 USD
1. jan. 2023
9,47 USD
1. jan. 2024
13,32 USD
1. jan. 2025
21,18 USD
CogState ROE historik
ÅRROEYoY
21,18 %+59,03%
13,32 %+40,69%
9,47 %-58,56%
22,84 %-4,93%
24,02 %-290,17%
-12,63 %-48,81%
-24,68 %+409,59%
-4,84 %-16,57%
-5,80 %-130,31%
19,15 %-138,27%
-50,05 %+72,01%
-29,10 %
Access this data via the Eulerpool API

CogState Aktieanalyse

Hvad laver CogState? CogState Ltd is an Australian company specializing in the development of innovative cognitive tests. The company was founded in 1999 and is based in Melbourne, Australia. It conducts computer-based cognitive tests to gather information about the cognitive functioning of patients and athletes. The CogState tests are specifically designed to measure cognitive abilities in areas such as perception, reaction time, memory, and attention. The business model of CogState is based on the development, marketing, and sale of cognitive test products. The company generates a significant portion of its revenue through licensing its tests to pharmaceutical and biotech companies that want to test their medications or therapies more effectively. CogState also has a strong presence in the sports industry, offering its tests to sports teams and individual athletes. CogState was founded in 1999 by Paul Maruff, a neuropsychologist, who was searching for better and more effective ways to conduct cognitive tests. Initially, the tests developed by CogState were exclusively for medical research, but it was quickly discovered that they could be useful in other areas as well. In 2004, Richard Kimber joined the company as CEO and Chairman, bringing his experience from the biotechnology industry. CogState offers a variety of cognitive tests for various applications, including clinical trials, sports performance analysis, and brain injury treatment. The tests are licensed by different companies and organizations that use them to test the effects of medications and therapies on cognitive functions or to assess performance and injuries in sports. One example of a CogState product is the AX Continuous Tracker Test. This test was developed for clinical use and allows for continuous and accurate measurement of cognitive functions in patients with psychiatric and neurological disorders. Another application is the SPARQ test for athletes, which allows for the measurement and improvement of athletes' cognitive abilities. In summary, CogState Ltd is a leading company in the field of cognitive tests. The company specializes in developing innovative cognitive tests for the specific requirements of pharmaceutical and biotech companies, as well as sports organizations. The tests are used worldwide by various organizations and have a significant impact on the treatment of psychiatric and neurological disorders, as well as performance and injury analysis in sports. CogState er et af de mest populære virksomheder på Eulerpool.com.

ROE i detaljen

Afkodning af egenkapitalforrentningen (ROE) for CogState

Egenkapitalforrentningen (ROE) for CogState er en grundlæggende finansiel nøgletal, der vurderer selskabets rentabilitet i forhold til egenkapitalen. ROE, som beregnes ved at dividere nettoindtjeningen med aktionærernes egenkapital, illustrerer, hvor effektivt selskabet genererer overskud på aktionærernes investeringer. En højere ROE indikerer øget effektivitet og profitabilitet.

År-til-år Sammenligning

Analyse af CogState's ROE på årsbasis hjælper med at følge rentabilitetstrends og den finansielle performance. En stigende ROE indikerer en forbedret rentabilitet og værdiskabelse for aktionærerne, mens en faldende ROE kan tyde på problemer med at generere overskud eller med håndteringen af egenkapitalen.

Effekter på Investeringer

ROE for CogState er afgørende for investorer, der vurderer selskabets rentabilitet, effektivitet og investeringsattraktivitet. En robust ROE angiver selskabets evne til at omdanne egenkapitalinvesteringer til overskud og øger dermed dens tiltrækningskraft for potentielle og nuværende investorer.

Fortolkning af ROE-udsving

Ændringer i CogState's ROE kan skyldes svingninger i nettoindtjeningen, egenkapitalen eller begge dele. Disse svingninger bliver undersøgt for at vurdere ledelseseffektiviteten, de finansielle strategier samt de forbundne risici og muligheder, og hjælpe investorer med at træffe velinformerede beslutninger.

Hyppigt stillede spørgsmål om CogState aktie

ROE (Return on Equity) for CogState er 21,18 % i 2026.

ROE (Return on Equity) for CogState ændrede sig fra 13,32 % til 21,18 %, hvilket repræsenterer en ændring på 59,03 %. Værdien er højere end i foregående år.

På Eulerpool kan du finde den fuldstændige historiske udvikling af ROE (Return on Equity) CogState siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

En 'god' varierer efter branche og virksomhedens udviklingsstadium. På Eulerpool kan du sammenligne ROE (Return on Equity)s CogState med konkurrenter og branchegjennemsnittet for at afgøre, om den er attraktiv.

For at evaluere ROE (Return on Equity)s er det afgørende at sammenligne det med andre virksomheder i samme branche og sektor. På Eulerpool kan du finde branchsammenligninger for ROE (Return on Equity).

Access this data via the Eulerpool API

Rentabilitet — CogState

Alle nøgletal — CogState